Becker's Healthcare January 17, 2025
CMS has named 15 additional prescription drugs, including diabetes medication Ozempic, for price negotiations under the Inflation Reduction Act. This marks the second round of negotiations aimed at reducing drug costs for Medicare beneficiaries.
The selected drugs account for approximately $41 billion in total spending under Medicare Part D between November 2023 and October 2024, or about 14% of Medicare Part D’s prescription drug costs, according to a Jan. 17 news release from the agency. The negotiated prices for these drugs will take effect in 2027.
The full list of drugs selected includes Ozempic, Rybelsus, Wegovy; Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet and Otezla.
These drugs are used...
Today's Sponsors
Today's Sponsor